Tick-borne diseases are becoming an increasing concern across the United States, with rising case counts and expanding geographic spread. While Lyme disease remains the most recognized infection, clinicians are now facing a broader range of pathogens and more complex cases involving co-infections.

In this episode of The Results Are In from Quest Diagnostics, host Anne Freeman sits down with Dr. Ann Salm, PhD, Director and Medical Science Liaison Lead for Infectious Disease and Immunology at Quest. Together, they walk through the growing burden of tick-borne illness, the environmental and ecological factors driving its rise, and why accurate diagnosis is becoming more challenging.

They break down the importance of timing when selecting diagnostic tests, explaining when molecular testing versus serologic testing is most effective. The conversation also explores the evolution of Lyme disease testing, from standard two-tier testing to the modified two-tier approach, and how newer methods can improve early detection.

Listeners will also gain insight into co-infections like anaplasmosis, ehrlichiosis, and babesiosis, and how comprehensive testing panels can support better clinical decision-making. The episode highlights how providers can approach testing strategically to improve patient outcomes in an increasingly complex diagnostic landscape.

Don’t miss this practical and timely discussion on how testing advancements are shaping the future of tick-borne disease management.

Follow Us

Twitter @QuestDX
Facebook @QuestDiagnostics

Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Abbreviations used in episode:

CDC: Centers for Disease Control and Prevention

IgG: Immunoglobulin G

IgM: Immunoglobulin M

STTT: Standard Two-Tier Testing

MTTT: Modified Two-Tier Testing

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Exocrine pancreatic insufficiency (EPI) is an underrecognized but clinically significant condition that can lead to malnutrition, weight loss, and long-term complications if left undiagnosed. Fortunately, there's a noninvasive and highly specific test that can help clinicians take the guesswork out of diagnosis.

In this episode of The Results Are In, host Jen Jenkins speaks with Dr Elif Nahas, Associate Director of Pathology and Chair of the Gastrointestinal and Liver Resource Committee at Quest Diagnostics. Dr Nahas explains what EPI is, the most common symptoms, and which patients are at highest risk. She also outlines how pancreatic elastase testing works, why it’s reliable even for patients already on pancreatic enzyme replacement therapy, and how to interpret test results accurately.

Whether you're a primary care provider or a GI specialist, this episode offers clear insights into why EPI should be on your diagnostic radar and how early identification and treatment can significantly improve patient outcomes.

Follow Us

Twitter @QuestDX
Facebook @QuestDiagnostics

Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Abbreviations used in episode:

EPI: Exocrine pancreatic insufficiency

AGA: American Gastroenterological Association

References mentioned in episode:

1. Quest Diagnostics Test Directory – Pancreatic Elastase-1, Fecal:
   https://testdirectory.questdiagnostics.com/test/test-detail/14693/pancreatic-elastase-1?cc=MASTER
2. American Gastroenterological Association (AGA):
   https://gastro.org

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The evolution of prenatal genetics is transforming care by supporting clarity, confidence, and a patient-centric approach.

In this episode of The Results Are In by Quest Diagnostics, host Lisa Demers is joined by Paul Kezmarsky, Director of Strategy & Solutions in Genetics at Quest. A board-certified genetic counselor, Paul brings over a decade of experience across both clinical and laboratory settings, with a focus on expanding access to care.

They explore how prenatal genetic screening has evolved from the days of limited biochemical tests to today’s broader, pan-ethnic screening approaches. They break down how these tests work, what makes them clinically useful, and why clear results supported by expert guidance are essential for providers and their patients.

This episode offers a straightforward look at how prenatal genetics is reshaping pregnancy care, making it more proactive, inclusive, and actionable for providers everywhere.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics
www.questdiagnostics.com

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.